Acquired Thrombotic Thrombocytopenic Purpura After ChAdOx1 nCoV-19 Vaccine: A Case Report
COVID-19, the illness caused by SARS-CoV-2, continues to cause significant morbidity and mortality across the world. An important step in overcoming SARS-CoV-2 is the global vaccination plan. Cases of acquired thrombotic thrombocytopenic purpura (aTTP) have been recently described after SARS-CoV-2 v...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
American College of Physicians
2022-07-01
|
| Series: | Annals of Internal Medicine: Clinical Cases |
| Online Access: | https://www.acpjournals.org/doi/10.7326/aimcc.2021.0110 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | COVID-19, the illness caused by SARS-CoV-2, continues to cause significant morbidity and mortality across the world. An important step in overcoming SARS-CoV-2 is the global vaccination plan. Cases of acquired thrombotic thrombocytopenic purpura (aTTP) have been recently described after SARS-CoV-2 vaccination. We describe a patient case of aTTP occurring 25 days after ChAdOx1 nCov-19 (Vaxzervria/AstraZeneca) vaccination that was promptly treated with plasma exchange, corticosteroids, rituximab, and caplacizumab. Remission of aTTP was achieved in 2 weeks and the patient is currently in complete remission. |
|---|---|
| ISSN: | 2767-7664 |